Advanced Medical Isotope Corp. (OTCMKTS:ADMD) recently updated on its IPs and trademark expansions, into the international market. It should be noted here that ADMD is a late stage radiation oncology focused, manufacturer of medical devices. The company stated that it has been actively pursuing patent and trademark protection of its brachytherapy products, as it gears up for introducing these products to the international market.
In its update, ADMD reaffirmed that its leading cancer treatment has been registered under the trademark of RadioGel™, worldwide. However, the registration of the trademark is still pending in China and Indonesia. Furthermore, in many of these countries, the registration spreads across multiple product classes. The company also revealed that it was currently negotiating with two companies, to further enhance its patent portfolio for brachytherapy products. It should be noted here that ADMD already has a robust patent portfolio, with several exclusive patent rights, for medical isotope manufacturing, processing and applications.
James C. Katzaroff, the CEO of Advance Medical Isotope, stated that the protection of its IPs, in both national and international markets is crucial, to ensure successful expansion into international markets. He expressed his confidence in the current trademark and patent protection efforts and stated that the company would continue to protect its IPs aggressively. In addition to this, Advance Medical announced that it would be partnering with Versant Medical Physics and Radiation Safety, to provide dosimetry expertise, for its brachytherapy devices. Dosimetry services would help ADMD determine the radiation dose to be administered to the human body, for its medical devices.
Mr. Katzaroff stressed on the importance of having expert help, when developing treatment plans for medical devices. He claimed that Versant had the appropriate expertise needed for these key services. One of the key reasons, for ADMD choosing Versant, is the fact that the agreement provides ADMD with the services of Dr. Darrell Fisher, who holds a total of seven patents, some of which have been used in the development of ADMD products.
Advanced Medical Isotope Corp. (OTCMKTS:ADMD) closed at a share price of $0.0033, at the end of the July 28 trading session. The stock moved up by 3.13%, over a trade volume of 3.84 million, during the session.
OXIS International, Inc. (OTCMKTS:OXIS) Acquires Rights To Develop and Commercialize TriKE Based Product
OXIS International, Inc. (OTCMKTS:OXIS) recently announced that its subsidiary, OXIS Bitoech, entered into an agreement with the University of Minnesota, for the user of Trispecific Killer Engager (TriKE). The technology had been developed by researchers at the university and the agreement now provides OXIS the right to develop and commercialize products, based on this technology. It should be noted here that TriKE tends to target NK cells to treat cancer. OXIS CEO, Anthony J. Cataldo, believes that the technology is a significant asset for the company. He also pointed out that TriKE kills cancerous cells effectively, without severe side effects. However, this has only been proven through pre-clinical models.